Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$388.18M+431.29%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mary Anne Heino
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,193
- Beta
- -0.06
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 5.56
Financials
Revenue
$388.18M+431.3%Net Income
$75.03M+1677.9%EBITDA
$115.44M+676.1%Free Cash Flow
$89.87M+598.9%EPS (diluted)
$1.11+753.8%Shares Outstanding (diluted)
67.52M+108.4%Operating Expenses
$141.64MCash & Debt
$593.30MReturn of Capital
$0.00Revenue by Segment (annual)
$4.51BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.54B | $233.56M | $3.46 |
| 2024 | $1.53B | $312.44M | $4.52 |
| 2023 | $1.30B | $326.66M | $4.79 |
| 2022 | $935.06M | $28.07M | $0.41 |
| 2021 | $425.21M | $-71.28M | $-1.06 |
| 2020 | $339.41M | $-13.47M | $-0.25 |
| 2019 | $347.34M | $31.67M | $0.81 |
| 2018 | $343.37M | $40.52M | $1.06 |
| 2017 | $331.38M | $123.39M | $3.31 |
| 2016 | $301.85M | $26.76M | $0.84 |
| 2015 | $293.46M | $-14.75M | $-0.60 |
| 2014 | $301.60M | $-3.56M | $-0.20 |
| 2013 | $283.67M | $-61.55M | $-3.40 |
| 2012 | $288.11M | $-42.00M | $-2.36 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $5.08
- Implied price
- $96.61
- Return from $99.96
- -0.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $48.03 — -51.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| -2.0% | -16.5% | -12.9% | -9.9% | -7.2% | -4.8% |
| 3.0% | -12.2% | -8.5% | -5.3% | -2.5% | 0.1% |
| 8.0% | -7.9% | -4.0% | -0.7% | 2.3% | 4.9% |
| 13.0% | -3.7% | 0.4% | 3.9% | 7.0% | 9.8% |
| 18.0% | 0.6% | 4.9% | 8.5% | 11.7% | 14.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+0.78%Social Signal Score
Mentions (9)
- Newsdefenseworld.net·5d ago·Positive
Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated “Hold” by Wall Street Analysts Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH - Get Free Report) have received an average rating of "Hold" from the fourteen research firms that are covering the stock, Marketbeat.com reports. Ten research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18) Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer
View source ↗ - Newsglobenewswire.com·14d ago·Negative
…ivalent to LUTATHERA® for the Treatment of GEP-NETs BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for BRAVNETSA™ (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equiv…
View source ↗ - Newsbusinesswire.com·38d ago·Neutral
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial m…
View source ↗ - News (Marketaux)gurufocus.com·39d ago·Positive
Bernard Horn's Top Q2 2026 Move: UniCredit SpA at a 1.5% Portfolio Impact The top holdings included 5.63% in SK hy[+217 characters]
View source ↗ - Newsreuters.com·53d ago·Negative
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment The U.S. Food and Drug Administration has approved a radioactive agent from Lantheus Holdings for use in brain scans to help assess patients for Alzheimer's disease, the company said on Friday.
View source ↗ - Newsglobenewswire.com·53d ago·Negative
…abeled Tau PET Imaging Agent for Alzheimer's Disease BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated fo…
View source ↗ - News (Marketaux)seekingalpha.com·56d ago·Positive
Lantheus Holdings: Why I Am Exiting Before The Merger Closes (NASDAQ:LNTH) On August 3, 2026, Lantheus <em[+329 characters]
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $1.26 per share
Typical surprise +0.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$1.55 vs $1.30beat
- Thu, May 7$1.46 vs $1.25beat
- Thu, Feb 26$1.67 vs $1.18beat
- Thu, Nov 6$1.27 vs $1.27beat
- Wed, Aug 6$1.57 vs $1.64miss
- Wed, May 7$1.53 vs $1.68miss
Estimates and results for LNTH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LNTH officers and directors.
- Bought
- —
- Sold
- $391.0m
0 trades
18 trades
- Patel Rajiv Asold
- Farallon Partners L L C/casold10 percent owner, other: Member of a Group Owning 10%·3,365,000 @ $56.15·$188.9m·Aug 20, 2025·filing
- Patel Rajiv Asold
- Farallon Partners L L C/casold
- Blanchfield Paulsold
- Niedzwiecki Danielsold
- Mchugh Juliesold
- Marshall Robert J. Jr.sold
82 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 12, 2025 (15d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 12, 2025 (30d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 12, 2025 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 12, 2025 (35d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.